Adverum Biotechnologies, Inc. has announced progress with yet another therapy designed to extend the time between anti-VEGF injections for treatment of wet age-related macular degeneration (wAMD). The company’s Investigational New Drug (IND) application has been approved for a multi-center study of ADVM-022, a novel gene therapy candidate for the treatment of wAMD.
“We are excited to have this IND active for ADVM-022, currently the only intravitreal gene therapy candidate entering the clinic for patients with wet AMD,” said Leone Patterson, interim president and chief executive officer of Adverum Biotechnologies.
Results of the phase 1 OPTIC trial, reported at the meeting of the American Academy of Ophthalmology in October 2019, revealed that ADVM-022 showed the ability to maintain vision with a one-time injection and was well-tolerated, with no serious adverse events (SAEs), no dose limiting toxicities (DLTs), and no Grade 3 adverse events.
Six leading retinal centers across the United States are participating in the Phase 1 trial, with each patient being followed for a total of 2 years.